Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer
Abstract
KRAS is mutated in the majority of pancreatic ductal adenocarcinoma. MAPK and PI3K-AKT are primary KRAS effector pathways, but combined MAPK and PI3K inhibition has not been demonstrated to be clinically effective to date. We explore the resistance mechanisms uniquely employed by malignant cells.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Nov 15, 2019
- Source ID
- 10.1158/1078-0432.ccr-19-1398
Entities
People
- Chang-il Hwang
- Daniel Öhlund
- Dannielle D Engle
- David A. Tuveson
- Dea Filippini
- Duncan I. Jodrell
- Hervé Tiriac
- Iok In Christine Chio
- Kenneth H. Yu
- Kevin Wright
- Kristopher K. Frese
- Lindsey A. Baker
- Mariano Ponz-sarvise
- Paul Smith
- Pearl Huang
- Tashinga E. Bapiro
- Tobiloba E Oni
- Vincenzo Corbo
- Youngkyu Park
Organizations
- AstraZeneca
- Cold Spring Harbor Laboratory
- Cornell University
- Formas
- Memorial Sloan Kettering Cancer Center
- National Institutes of Health
- Stony Brook University
- The Starr Foundation
- University of Cambridge
- University of Colorado Cancer Center